ArticleMolecular biology reports2025
Development of high-affinity peptide probes for improved diagnosis of Hashimoto's thyroiditis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune thyroid diseases (AITDs), including Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), result from the immune system attacking the thyroid gland, leading to hypothyroidism or hyperthyroidism. Detection of anti-thyroid peroxidase antibodies (anti-TPO) is crucial for diagnosing autoimmune hypothyroidism. However, achieving consistent sensitivity and specificity across diagnostic platforms remains a challenge.
methodsThis study aimed to identify and validate synthetic peptide epitopes derived from immunodominant regions (IDR-A and IDR-B) of the thyroid peroxidase (TPO) enzyme to improve anti-TPO antibody detection. Seven peptides with high antigenicity scores were selected using bioinformatics tools such as Immune Epitope Database (IEDB), ABCpred, and BcePred. These biotinylated peptides were synthesized and evaluated for their ability to bind anti-TPO antibodies in patient sera using direct and competitive Enzyme-Linked Immunosorbent Assay (ELISA) assays. A total of 240 serum samples (120 anti-TPO positive and 120 negative) by standard ELISA were analyzed to assess sensitivity, specificity, and overall diagnostic performance.
resultsOf the seven peptides, P1 showed the highest sensitivity (63.64%) and the largest area under the receiver operating characteristic (ROC) curve (area under the curve (AUC)) = 0.8450. Peptides P4, P5, and P6 demonstrated superior specificity (> 94%). Competitive ELISA revealed that peptide P7 significantly inhibited anti-TPO antibody binding to the TPO protein, with optimal inhibition observed at 100 µg/mL. Statistical analysis confirmed the diagnostic relevance of these peptides, with significant differences in Optical Density (OD) between peptide-treated and untreated samples (p < 0.0001).
conclusionAmong the identified peptides, P1 and P7 are particularly promising as antigenic probes for detecting anti-TPO antibodies in AITDs. Their application may enhance the sensitivity and specificity of diagnostic assays, addressing current limitations in clinical testing. This peptide-based approach could facilitate the development of population-specific diagnostic kits that account for genetic variation in TPO epitopes.
Indexed as
Identifiers
40928690What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.